FDA Halts Enrollment on Tazemetostat Trials

April 23, 2018 – The FDA has halted enrollment on clinical trials of tazemetostat in patients with various solid tumors and hematologic malignancies, according to Epizyme, the manufacturer of the EZH2 inhibitor. Previously enrolled patients without disease progression can continue on study. The FDA placed the partial clinical hold on the tazemetostat program after Epizyme provided a safety update detailing a pediatric patient with advanced poorly differentiated … (leggi tutto)